Five things for pharma marketers to know: Wednesday, May 4, 2016

1. The FDA said there have been rare cases of patients taking the antipsychotic medication Abilify who have reported uncontrollable urges to gamble, eat, shop, and engage in sexual activity. There is a generic version of the drug as well as brand-name versions marketed by Otsuka Pharmaceutical and Alkermes. (WSJ)

2. Martin Shkreli, former CEO of Turing Pharmaceuticals, may face additional charges of securities fraud related to his work with another drugmaker, Retrophin, a federal prosecutor said in court. Shkreli was arrested in December on securities charges related to Retrophin. (Reuters)

3. Stand Up To Cancer and Genentech launched a campaign called "Be the Breakthrough,” which seeks to educate Americans about cancer, including how to participate in screenings and clinical trials.

4. Precision for Medicine acquired Applied Immunology, which develops and delivers custom cell-based and immunoassay solutions. The company in March acquired ACT Oncology, a clinical research organization.

5. ICYMI: Indegene Lifesystems, a healthcare IT company, acquired Skura Technologies for $9 million as part of an effort to broaden its technology offerings to pharmaceutical companies. (The Economic Times)